Cesario V. Borlongan – författare

Respected investigators from around the world critically review what is known about the role of mitochondrial inhibitors in cell death and the onset of neurodegeneration. These distinguished researchers - many pioneers in the field - detail the symptomology, origin, and chemistry of mitochondrial toxins, and discuss animal models of human diseases related to abnormal mitochondrial function. The emphasis on 3-NP and its ability to replicate the cellular, anatomical, and behavioral alterations seen in Huntington's disease demonstrate that mitochondrial inhibitors play an important role in the etiology of central nervous system disorders. The book also discusses recent therapeutic modalities aimed at rescuing the central nervous system from abnormal mitochodrial functioning. With its timely, in-depth review, Mitochondrial Inhibitors and Neurodegenerative Disorders offers today's advanced investigators powerful insights into how mitochondrial toxins precipitate and exacerbate neurodegenerative disorders, and details important new treatment strategies that can halt or reverse disease progression.

An authoritative survey of the most recent scientific evidence showing how cyclosporin, FK-506, and their analogs-the neuroimmunophilins-evolved from being purely immunosuppressant "drugs" to neuroprotective "agents". The book focuses on recent preclinical evidence that demonstrates the neurotrophic/neuroprotective effects of immunosuppressants when administered alone or when combined with neural transplantation therapy in animal models of neurological disorders. It also discusses their efficacy and mechanisms of action in vitro and in vivo models of CNS disease, and provides laboratory studies with compelling clinical indications for Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, ALS, sciatic nerve injury, and drug addiction.

An authoritative survey of the most recent scientific evidence showing how cyclosporin, FK-506, and their analogs-the neuroimmunophilins-evolved from being purely immunosuppressant "drugs" to neuroprotective "agents". The book focuses on recent preclinical evidence that demonstrates the neurotrophic/neuroprotective effects of immunosuppressants when administered alone or when combined with neural transplantation therapy in animal models of neurological disorders. It also discusses their efficacy and mechanisms of action in vitro and in vivo models of CNS disease, and provides laboratory studies with compelling clinical indications for Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, ALS, sciatic nerve injury, and drug addiction.